A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 7, 2008, Pages 2305-2312

  Garcia Effron, Guillermo ^a   Katiyar, Santosh K ^b   Park, Steven ^a   Edlind, Thomas D ^b   Perlin, David S ^a  

^a PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN; FUNGAL PROTEIN; GLUCAN SYNTHASE; MICAFUNGIN; PROLINE; PROTEIN FKS1P;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIBIOTIC SENSITIVITY; ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA METAPSILOSIS; CANDIDA ORTHOPSILOSIS; CANDIDA PARAPSILOSIS; ENZYME INHIBITION; FUNGUS ISOLATION; KINETICS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PARAMETER; PHENOTYPE; PRIORITY JOURNAL; SEQUENCE ANALYSIS;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIFUNGAL AGENTS; BASE SEQUENCE; CANDIDA; CANDIDIASIS; DNA PRIMERS; DNA, FUNGAL; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; ENZYME INHIBITORS; FUNGAL PROTEINS; GENE EXPRESSION; GENES, FUNGAL; GLUCOSYLTRANSFERASES; HUMANS; MEMBRANE PROTEINS; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; SACCHAROMYCES CEREVISIAE PROTEINS; SEQUENCE HOMOLOGY, AMINO ACID; SPECIES SPECIFICITY;

EID: 46249106060     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00262-08     Document Type: Article

References (36)

1. Almirante, B., D. Rodriguez, M. Cuenca-Estrella, M. Alniela, F. Sanchez, J. Ayats, C. Alonso-Tarres, J. L. Rodriguez-Tudela, and A. Pahissa. 2006. Epidemiology, risk factors, and prognosis of Candida parapsilosis bloodstream infections: case-control population-based surveillance study of patients in Barcelona, Spain, from 2002 to 2003. J. Clin. Microbiol. 44:1681-1685.
2. Balashov, S. V., S. Park, and D. S. Perlin. 2006. Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1. Antimicrob. Agents Chemother. 50:2058-2063.
3. Bennett, J. E. 2006. Echinocandins for candidemia in adults without neutropenia. N. Engl. J. Med. 355:1154-1159.
4. Brito, L. R., T. Guimaraes, M. Nucci, R. C. Rosas, L. Paula Almeida, D. A. Da Matta, and A. L. Colombo. 2006. Clinical and microbiological aspects of candidemia due to Candida parapsilosis in Brazilian tertiary care hospitals. Med. Mycol. 44:261-266.
5. Cheung, C., Y. Guo, P. Gialanella, and M. Feldmesser. 2006. Development of candidemia on caspofungin therapy: a case report. Infection 34:345-348.
6. Colombo, A. L., T. Guimaraes, L. R. Silva, L. P. de Almeida Monfardini, A. K. Cunha, P. Rady, T. Alves, and R. C. Rosas. 2007. Prospective observational study of candidemia in Sao Paulo, Brazil: incidence rate, epidemiology, and predictors of mortality. Infect. Control Hosp. Epidemiol. 28:570-576.
7. Colombo, A. L., M. Nucci, B. J. Park, S. A. Nouer, B. Arthington-Skaggs, D. A. da Matta, D. Warnock, and J. Morgan. 2006. Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers. J. Clin. Microbiol. 44:2816-2823.
8. Denning, D. W. 2003. Echinocandin antifungal drugs. Lancet 362:1142-1151.
9. Douglas, C. M., F. Foor, J. A. Marrinan, N. Morin, J. B. Nielsen, A. M. Dahl, P. Mazur, W. Baginsky, W. Li, and M. el Sherbeini. 1994. The Saccharomyces cercvisiae FKS1 (ETG1) gene encodes an integral membrane protein which is a subunit of 1,3-beta-D-glucan synthase. Proc. Natl. Acad. Sci. USA 91:12907-12911.
10. Douglas, C. M., J. A. D'Ippolito, G. J. Shei, M. Meinz, J. Onishi, J. A. Marrinan, W. Li, G. K. Abruzzo, A. Flattery, K. Bartizal, A. Mitchell, and M. B. Kurtz. 1997. Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-β-D-glucan synthase inhibitors. Antimicrob. Agents Chemother. 41:2471-2479.
11. Edlind, T. D., K. W. Henry, J. P. Vermitsky, M. P. Edlind, S. Raj, and S. K. Katiyar. 2005. Promoter-dependent disruption of genes: simple, rapid, and specific PCR-based method with application to three different yeast. Curr. Genet. 48:117-125.
12. Espinel-Ingroff, A. 2003. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev. Iberoam. Micol. 20:121-136.
13. Forrest, G. N., E. Weekes, and J. K. Johnson. 2008. Increasing incidence of Candida parapsilosis candidemia with caspofungin usage. J. Infect. 56:126-129.
14. Gomez-Lopez, A., A. Alastruey-Izquierdo, D. Rodriguez, B. Almirante, A. Pahissa, J. Rodriguez-Tudela, and M. Cuenca-Estrella. 2008. Prevalence and susceptibility profile of Candida metapsilosis and Candida orthopsilosis: results from population-based surveillance of candidemia in Spain. Antimicrob. Agents Chemother. 52:1506-1509.
15. Katiyar, S., M. Pfaller, and T. Edlind. 2006. Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility. Antimicrob. Agents Chemother. 50:2892-2894.
16. Mazur, P., N. Morin, W. Baginsky, M. el Sherbeini, J. A. Clemas, J. B. Nielsen, and F. Foor. 1995. Differential expression and function of two homologous subunits of yeast 1,3-β-D-glucan synthase. Mol. Cell. Biol. 15: 5671-5681.
17. Melo, A. S., A. L. Colombo, and B. A. Arthington-Skaggs. 2007. Paradoxical growth effect of caspofungin observed on biofilms and planktonic cells of five different Candida species. Antimicrob. Agents Chemother. 51:3081-3088.
18. Morrison, V. A. 2006. Echinocandin antifungals: review and update. Expert Rev. Anti Infect. Ther. 4:325-342.
19. NCCLS. 2002. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard, 2nd ed. NCCLS document M27-A2. National Committee for Clinical Laboratory Standards, Wayne, PA.
20. Odds, F. C., M. Motyl, R. Andrade, J. Bille, E. Canton, M. Cuenca-Estrella, A. Davidson, C. Durassel, D. Ellis, E. Foraker, A. W. Fothergill, M. A. Ghannoum, R. A. Giacobbe, M. Gobernado, R. Handke, M. Laverdiere, W. Lee-Yang, W. G. Merz, L. Ostrosky-Zeichner, J. Peman, S. Perea, J. R. Perfect, M. A. Pfaller, L. Proia, J. H. Rex, M. G. Rinaldi, J. L. Rodriguez-Tudela, W. A. Schell, C. Shields, D. A. Sutton, P. E. Verweij, and D. W. Warnock. 2004. Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J. Clin. Microbiol. 42:3475-3482.
21. Park, S., R. Kelly, J. N. Kahn, J. Robles, M. J. Hsu, E. Register, W. Li, V. Vyas, H. Fan, G. Abruzzo, A. Flattery, C. Gill, G. Chrebet, S. A. Parent, M. Kurtz, H. Teppler, C. M. Douglas, and D. S. Perlin. 2005. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob. Agents Chemother. 49:3264-3273.
22. Perlin, D. S. 2007. Resistance to echinocandin-class antifungal drugs. Drug Resist. Updat. 10:121-130.
23. Pfaffl, M. W. 2001. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29:e45.
24. Pfaller, M. A., L. Boyken, R. J. Hollis, J. Kroeger, S. A. Messer, S. Tendolkar, and D. J. Diekema. 2008. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J. Clin. Microbiol. 46:150-156.
25. Pfaller, M. A., L. Boyken, R. J. Hollis, S. A. Messer, S. Tendolkar, and D. J. Diekema. 2006. Global surveillance of in vitro activity of micafungin against Candida: a comparison with caspofungin by CLSI-recommendcd methods. J. Clin. Microbiol. 44:3533-3538.
26. Pfaller, M. A., L. Boyken, R. J. Hollis, S. A. Messer, S. Tendolkar, and D. J. Diekema. 2005. In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole. J. Clin. Microbiol. 43:5425-5427.
27. Pfaller, M. A., L. Boyken, R. J. Hollis, S. A. Messer, S. Tendolkar, and D. J. Diekema. 2006. In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance. J. Clin. Microbiol. 44:760-763.
28. Pfaller, M. A., and D. J. Diekema. 2007. Epidemiology of invasive candidiasis: a persistent public health problem. Clin. Microbiol. Rev. 20:133-163.
29. Pfaller, M. A., D. J. Diekema, D. L. Gibbs, V. A. Newell, K. P. Ng, A. Colombo, J. Finquelievich, R. Barnes, and J. Wadula. 2008. Geographic and temporal trends in isolation and antifungal susceptibility of Candida parapsilosis: a global assessment from the ARTEMIS DISK antifungal surveillance program. 2001 to 2005. J. Clin. Microbiol. 46:842-849.
30. Rossignol, T., M. E. Logue, K. Reynolds, M. Grenon, N. F. Lowndes, and G. Butler. 2007. Transcriptional response of Candida parapsilosis following exposure to farnesol. Antimicrob. Agents Chemother. 51:2304-2312.
31. Safdar, A., T. W. Bannister, and Z. Safdar. 2004. The predictors of outcome in immunocompetent patients with hematogenous candidiasis. Int. J. Infect. Dis. 8:180-186.
32. Safdar, A., D. Perlin, and D. Armstrong. 2002. Hematogenous infections due to Candida parapsilosis: changing trends in fungemic patients at a comprehensive cancer center during the last four decades. Diagn. Microbiol. Infect. Dis. 44:11.
33. Saiman, L., E. Ludington, J. D. Dawson, J. E. Patterson, S. Rangel-Frausto, R. T. Wiblin, H. M. Blumberg, M. Pfaller, M. Rinaldi, J. E. Edwards, R. P. Wenzel, and W. Jarvis. 2001. Risk factors for Candida species colonization of neonatal intensive care unit patients. Pediatr. Infect. Dis. J. 20:1119-1124.
34. Smith, W. L., and T. D. Edlind. 2002. Histone deacetylase inhibitors enhance Candida albicans sensitivity to azoles and related antifungals: correlation with reduction in CDR and ERG upregulation. Antimicrob. Agents Chemother. 46:3532-3539.
35. Tavanti, A., A. D. Davidson, N. A. Gow, M. C. Maiden, and F. C. Odds. 2005. Candida orthopsilosis and Candida metapsilosis spp. nov. to replace Candida parapsilosis groups II and III. J. Clin. Microbiol. 43:284-292.
36. Wiederhold, N. P., and R. E. Lewis. 2003. The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy. Expert Opin. Investig. Drugs 12:1313-1333.